NVO - Novo Nordisk Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs | Benzinga
The unprecedented demand for weight loss drugs, including Novo Nordisk A/S’s (NYSE:NVO) Wegovy and Eli Lilly And Co’s (NYSE:LLY) Zepbound, has created a supply crunch, leaving patients struggling to access these injectable treatments.
With obesity medications expected to reach 15 million U.S. adults by 2030, the weight loss drug market could potentially be valued at $100 billion by the end of the decade.
Novo Nordisk and Eli Lilly are actively working to increase supply to meet the demand spikes. Both companies have recently provided updates on their positive supply developments, assuring investors and patients.
Novo Nordisk revealed significant progress in increasing the supply of its lower-dose versions of Wegovy in January, doubling the availability compared to previous months.
“I think it’s going to take a few years for it to ...